The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neo-adjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.

Dugo M, Huang CS, Egle D, Bermejo B, Zamagni C, Seitz RS, Nielsen TJ, Thill M, Antón-Torres A, Russo S, Ciruelos EM, Schweitzer BL, Ross DT, Galbardi B, Greil R, Semiglazov V, Gyorffy B, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Blasi O, Callari M, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G.

Clin Cancer Res. 2024 Sep 23:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-0149. Online ahead of print. PMID: 39308141.

https://pubmed.ncbi.nlm.nih.gov/39308141/